Pharmacokinetic Research in Pediatric HIV/TB Co-Infection (R21)

Post Date

March 3rd 2010

Application Due Date

August 24th 2010

Funding Opportunity Number

RFA-HD-09-016

CFDA Number(s)

93.242
93.865

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health
Income Security and Social Services

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Award Range:

  $None - $None

Grant Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), encourages Exploratory/Developmental Research Grant Award (R21) applications from institutions/organizations that propose to evaluate the pharmacokinetics of anti-tuberculosis (anti-TB) drugs and pharmacokinetic drug interactions between anti-TB drugs and anti-HIV medications in children with HIV/TB co-infection. Research in this area lags far behind that in adults due to the many challenges surrounding the diagnosis and management of TB disease in children. Research related to the treatment of TB in the context of pediatric HIV/TB co-infection is urgently needed. This FOA will support investigator-initiated grants to define appropriate dosing of anti-TB agents in HIV-infected children and will generate knowledge leading to the optimization of management of TB/HIV co-infection in children, including the management of central nervous system (CNS) involvement with TB through the evaluation of CNS penetration of anti-TB agents in the context of antiretroviral therapy. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental Research Grant (R21) award mechanism and is issued in parallel with an FOA of identical scientific scope, RFA-HD-09-015 that encourages applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The NICHD intends to commit $250,000 (total costs), and NIMH intends to commit $150,000 (total costs) in FY 2010 to support one to two meritorious applications. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-09-016.html